Ask A Heart Surgeon: The Truth About "Reversing" Coronary Artery Plaque

Summary

Dr. Michael Richman—introduced in the subtitles as “Michael Richmond”—questions whether a reduction in plaque volume on coronary imaging proves that plaque has physically left the artery. He argues that imaging can show changes in plaque size and composition, but cannot by itself distinguish true removal of plaque material from compaction and stabilization within the artery wall.

Main ideas

• A smaller plaque measurement does not necessarily mean plaque mass was removed. The speaker says coronary CT and intravascular ultrasound measure features such as volume and density, not the movement of individual cholesterol molecules. He says human studies have not directly traced the complete process of plaque material leaving a living coronary artery.

• Two possible explanations for plaque reduction:

  • True regression: Cholesterol and cellular debris leave the artery wall.
  • Stabilization or compaction: Soft, lipid-rich plaque becomes less inflamed, denser, more fibrous, or calcified, taking up less space without necessarily disappearing.

• Closet analogy: The speaker compares plaque to bulky, damp boxes in a crowded closet. Removing the boxes represents true regression; drying, flattening, and stacking them represents stabilization. In either case, the closet takes up less space, but only the first means the material has left.

• How plaque removal is thought to work in animal models: The speaker describes four steps observed in mice after a major reduction in circulating apoB or LDL particles:

  1. Lower blood cholesterol reduces the entry of new lipoproteins into the artery wall.
  2. Cholesterol efflux increases: functional HDL helps remove cholesterol from macrophages, a process called reverse cholesterol transport.
  3. Macrophages shift toward a healing state rather than accumulating in the artery wall.
  4. Inflammation subsides, and immune activity helps clear remnants of dead cells.

He says researchers have tracked these processes in animals using labeled cholesterol, cell examination, and immune-cell tracking. He contrasts this with the difficulty of conducting equivalent destructive or invasive tracking in living human coronary arteries.

• Human imaging findings can fit the stabilization explanation. The speaker says CT classifies plaque by density, including calcified and non-calcified plaque. He cites studies such as GLAGOV, in which lower LDL levels were associated with some reduction in total plaque volume while calcified plaque increased or remained stable. He argues that this pattern could reflect soft plaque becoming denser and more calcified—not necessarily leaving the artery.

• Clinical and scientific distinction: The speaker describes stabilized, compact plaque as less likely to rupture than soft, inflamed plaque and says stabilization benefits patients. However, he cautions that calling a measured volume reduction proof of physical plaque removal goes beyond what imaging alone establishes.

Bottom line

In the speaker’s view, the cellular machinery for true plaque removal has been demonstrated in animal biology, but current human imaging cannot tell whether plaque has exited the artery or has instead been condensed and remodeled within it. He favors describing scan-measured reductions as plaque reduction and stabilization rather than definitive proof of mass removal.

The closing remarks include an ambiguous statement in the auto-generated subtitles about whether studies prove a reduction in serious cardiovascular events. This sits uneasily alongside the speaker’s earlier statement that stabilization reduces heart-attack risk.

Speakers and sources featured

• Speaker: Dr. Michael Richman, a cardiothoracic surgeon; the subtitles render his surname as “Richmond” in his introduction.
• Research discussed: Mouse and other animal plaque-regression studies, and the human GLAGOV study involving PCSK9 inhibitors. No other speakers are identified.